• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    Cardiome Announces Licensing Agreement for XYDALBA

    Bryan Mc Govern
    Jun. 21, 2017 09:13AM PST
    Pharmaceutical Investing

    Cardiome Pharma announced its affiliate has signed an exclusive license and distribution agreement with Tzamal Medical, which will move XYDALBA closer to commercialization in Israel.

    Cardiome Pharma (NASDAQ:CRME; TSX:COM) announced its affiliate has signed an exclusive license and distribution agreement with Tzamal Medical, which will move XYDALBA closer to commercialization in Israel.
    As quoted in the press release:

    As part of the agreement, Tzamal will be responsible for obtaining regulatory and pricing approvals for XYDALBA™ from Israel’s Ministry of Health. Cardiome will receive an upfront payment, as well as additional payments, based upon commercial achievements and sales of XYDALBA™. Additional terms were not disclosed.
    “Tzamal is a proven leader at providing Israel’s hospitals with high-quality medications across a number of therapeutic areas including anti-infectives,” said Hugues Sachot, Cardiome’s Chief Commercial Officer. “Cardiome recently announced its launch of XYDALBA™ in the major markets of the U.K., France and Germany, and extending the availability of XYDALBA™ to Israel is a logical step in commercializing this important medicine across the territories we cover.”
    “Based on the high-quality registration file of XYDALBA™, we expect to complete a timely registration and launch within the next 12 to 18 months, and we are confident that the product’s unique benefits will position it as a first-choice treatment for its approved indications and the important underserved market segment it targets,” said Edi Steinberg, General Manager of Tzamal Bio Pharma Ltd.

    Click here to read the full press release.

    Source: www.newswire.ca

    pharmaceutical investingdistribution agreementgermanyexclusive licensecardiome pharma
    The Conversation (0)

    Go Deeper

    AI Powered
    Microscopic view of stem cells.

    Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

    Medical pills branded with Canadian flag.

    Canadian Pharma Stocks: 5 Biggest Companies

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Invion Limited

    IVX:AU

    Cardiol Therapeutics

    CRDL:CA
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×